The company signed an agreement with the US Food and Drug Administration (FDA) regarding the trial’s design. The phase 3 HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS
The company submitted a biologics licence application (BLA) to the US Food and Drug Administration (FDA) to market the vaccine for the prevention of herpes zoster (shingles) in
In the '482 study, a total of 1,718 patients were randomized to receive either subcutaneous XGEVA 120 mg and intravenous placebo every four weeks, or intravenous zoledronic acid
The drug, revefenacin, a once-daily nebulized bronchodilator, met primary efficacy endpoint and is shown to be well-tolerated in both studies. The studies, which lasted for 12 weeks, included
RXi is a clinical-stage RNAi firm focused on the development of new therapeutics to solve significant unmet medical needs. As per the deal terms, RXi would issue stock
SCIB2 will be studied in combination with a checkpoint inhibitor and follow the publication of data in journal OncoImmunology, which showed the drug demonstrated potent anti-tumour immunity. Data
The spray is approved to treat allergic and non-allergic rhinitis, which is an inflammation of the inside of the nose, and nasal polyps, which cause a swelling of
The injection has been approved as a short-term replacement therapy for oral carbamazepine formulations in adults with certain seizure types when oral administration is temporarily not possible. It
German life sciences firm Merck has opened a new biopharmaceuticals production and development support center in the Songdo district of Incheon, Korea. The M Lab Collaboration Center offers
The drug, called Zubsolv, is a formulation of buprenorphine, a semisynthetic opioid derivative of thebaine, and naloxone, an opioid overdose antidote. The new low dose, 0.7mg/0.18 mg, Zubsolv
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.